<DOC>
	<DOCNO>NCT01137812</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety canagliflozin compare sitagliptin patient type 2 diabetes mellitus receive treatment metformin sulphonylurea inadequate glycemic ( blood sugar ) control .</brief_summary>
	<brief_title>The CANTATA-D2 Trial ( CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial )</brief_title>
	<detailed_description>Canagliflozin drug test see may useful treat patient diagnose type 2 diabetes mellitus ( T2DM ) . This randomize ( study drug assign chance ) , double-blind ( neither patient study doctor know name assign treatment ) , multicenter study determine efficacy , safety , tolerability canagliflozin 300 mg compare sitagliptin 100 mg ( antihyperglycemic drug ) patient T2DM achieve adequate response current antihyperglycemic therapy metformin sulphonylurea control diabetes . Approximately 720 patient T2DM receive combination therapy metformin sulphonylurea receive addition once-daily treatment canagliflozin 300 mg sitagliptin 100 mg capsule 52 week . Patients participate study approximately 59 72 week . During treatment , patient monitor safety review adverse event , result laboratory test , 12-lead electrocardiogram ( ECGs ) , vital sign measurement , body weight , physical examination , self monitor blood glucose ( SMBG ) measurement . The primary outcome measure study effect canagliflozin compare sitagliptin hemoglobin A1c ( HbA1c ) 52 week treatment . Study drug take orally ( mouth ) daily first meal day unless otherwise specify . Patients take single-blind placebo 2 week randomization . After randomization , patient study take double-blind canagliflozin 300 mg match sitagliptin 100 mg 52 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>All patient must diagnosis T2DM currently treat metformin sulphonylurea Patients study must HbA1c &gt; =7 &lt; =10.5 % fast plasma glucose ( FPG ) &lt; 300 mg/dL ( 16.7 mmol/L ) History diabetic ketoacidosis , type 1 diabetes mellitus ( T1DM ) , pancreas beta cell transplantation , diabetes secondary pancreatitis pancreatectomy severe hypoglycemic episode within 6 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Canagliflozin</keyword>
	<keyword>Sitagliptin ( Januvia )</keyword>
	<keyword>Metformin</keyword>
	<keyword>Sulphonylurea</keyword>
	<keyword>Hemoglobin A1c</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
</DOC>